Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
A prospective, single-arm, non-randomized, multi-center, open-label study following patients
with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields
(PEF) ablation who may be candidates for standard of care neoadjuvant use of checkpoint
inhibitor (nivolumab) treatment plus platinum doublet chemotherapy.